Unknown Analyst

Can you can just take the opportunity to go through maybe an introduction of the company and what are some key long-term growth drivers.

Michael Cordonnier
Co-Founder, Chairman, CEO & President

Yes, I would love to. So co-founded Carlsmed in 2018, really with the mission to improve clinical outcomes and reduce the cost of health care for spine surgery and beyond. And so we built this technology platform that allows us to take preoperative data about patients, data about surgeons, create a 3-dimensional digital model, the patient's pathology, the optimal surgical plan and then 3D-print all the devices that are needed for that surgery. And it's a really different business model for a med tech company. We have an AI-enabled platform that allows us to do everything digitally for the surgery first and then custom make 3D-printed devices for that surgery. And we've developed this platform now for lumbar spine surgery and most recently, cervical spine surgery.

Unknown Analyst

So what do you think that maybe the market is still underappreciating because obviously, it's a very clearly differentiated story.

Michael Cordonnier
Co-Founder, Chairman, CEO & President

Well, it's super early days, and we recently published our 2-year outcome data on the lumbar platform showing that by using the aprevo platform, surgeons can reduce the revision rate for patients for lumbar spine fusion surgery by 74% at a 2-year time point. And it's really phenomenal because it's the first technology for this patient population that's meaningfully improved outcomes. And we talk about our mission of improving outcomes, reducing the cost of care, we're able to really achieve both of those because these are typically patients that are